Expanded Access to Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrent Prostate Cancer

NCT05415228 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2023-05-18

No results posted yet for this study

Summary

This is an expanded access program using 68Ga PSMA-HBED-CC (68Ga-PSMA-11).

The primary goal of this expanded access program is to make 68Ga PSMA-11 PET/CT imaging available to patients.

Conditions

  • Prostate Adenocarcinoma

Interventions

DRUG

68Ga-PSMA-11

68Ga-PSMA-11 is a radiopharmaceutical for the detection of prostate cancer using PET/CT imaging

Sponsors & Collaborators

  • Morand Piert, MD

    lead OTHER

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05415228 on ClinicalTrials.gov